ArticleMolecular medicine reports2017
MicroRNA-130a is upregulated in colorectal cancer and promotes cell growth and motility by directly targeting forkhead box F2.
Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Tissue micro-RNAs associated with colorectal cancer prognosis: a systematic review.Molecular biology reports · 2021Pooled it
- Integrated analysis of non‑coding RNAs (HOTAIR and miR‑130a) and their cross‑talk with TGF‑β1, SIRT1 and E‑cadherin as potential biomarkers in colorectal cancer.Oncology letters · 2025Article
- Transcription factor FOXD1 and miRNA-204-5p play a major role in B4GALNT2 downregulation in colon cancer.Scientific reports · 2025Article
- Article
- Aberrant DNA Methylation-Mediated FOXF2 Dysregulation Is a Prognostic Risk Factor for Gastric Cancer.Frontiers in molecular biosciences · 2021Article
- The regulatory roles and mechanisms of the transcription factor FOXF2 in human diseases.PeerJ · 2021Article
- Unveiling role of sphingosine-1-phosphate receptor 2 as a brake of epithelial stem cell proliferation and a tumor suppressor in colorectal cancer.Journal of experimental & clinical cancer research : CR · 2020Article
- FOXF2 acts as a crucial molecule in tumours and embryonic development.Cell death & disease · 2020Review
- Low-Temperature Plasma Suppresses Proliferation and Induces Apoptosis in Lung Cancer Cells by Regulating the miR-203a/BIRC5 Axis.OncoTargets and therapy · 2020Article
- The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis.Molecular cancer · 2019Review
- Relevance of MicroRNAs as Potential Diagnostic and Prognostic Markers in Colorectal Cancer.International journal of molecular sciences · 2018Review
- FOXF2 Regulates PRUNE2 Transcription in the Pathogenesis of Colorectal Cancer.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the most prevalent cancers among males and females worldwide. Despite progress in diagnostic and therapeutic strategies for CRC patients, the prognosis for patients with advanced CRC remains poor. MicroRNAs (miRNAs/miRs) are a class of highly conserved short, endogenously expressed and single‑stranded non‑coding RNAs. In recent years, increasing studies have demonstrated that dysregulation of miRNAs is closely associated with CRC carcinogenesis and progression. The aim of the present study was to explore the expression, roles and underlying molecular mechanism of miR‑130a in CRC. The results indicated that miR‑130a was significantly upregulated in CRC, and that miR‑130a expression levels were correlated with TNM stage and lymph node metastasis of CRC. Inhibition of miR‑130a markedly suppressed colorectal cancer cell proliferation, migration and invasion. Furthermore, forkhead box F2 (FOXF2) was identified as a direct downstream target gene of miR‑130a in colorectal cancer. Downregulation of FOXF2 could partially reverse the functions induced by miR‑130a under‑expression in CRC cells. These findings suggested that miR‑130a can regulate FOXF2 and function as an oncogene in CRC. Therefore, miR‑130a may serve as a useful therapeutic agent for miRNA‑based CRC targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.